SG11202100531RA - Novel thiazole derivatives and pharmaceutically acceptable salts thereof - Google Patents
Novel thiazole derivatives and pharmaceutically acceptable salts thereofInfo
- Publication number
- SG11202100531RA SG11202100531RA SG11202100531RA SG11202100531RA SG11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA SG 11202100531R A SG11202100531R A SG 11202100531RA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- thiazole derivatives
- novel thiazole
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180111001 | 2018-09-17 | ||
| PCT/KR2019/011887 WO2020060112A1 (en) | 2018-09-17 | 2019-09-11 | Novel thiazole derivatives and pharmaceutically acceptable salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100531RA true SG11202100531RA (en) | 2021-02-25 |
Family
ID=69887568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100531RA SG11202100531RA (en) | 2018-09-17 | 2019-09-11 | Novel thiazole derivatives and pharmaceutically acceptable salts thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20210284658A1 (en) |
| EP (1) | EP3853225B1 (en) |
| JP (1) | JP7235859B2 (en) |
| KR (2) | KR102130253B1 (en) |
| CN (1) | CN112739695A (en) |
| AU (1) | AU2019344240B2 (en) |
| BR (1) | BR112021004999A2 (en) |
| CA (1) | CA3106855A1 (en) |
| CL (1) | CL2021000594A1 (en) |
| CO (1) | CO2021003412A2 (en) |
| EA (1) | EA202190558A1 (en) |
| IL (1) | IL280639B (en) |
| MX (1) | MX2021002456A (en) |
| PH (1) | PH12021550572A1 (en) |
| SG (1) | SG11202100531RA (en) |
| TW (1) | TW202023548A (en) |
| UA (1) | UA125427C2 (en) |
| WO (1) | WO2020060112A1 (en) |
| ZA (1) | ZA202101652B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102335637B1 (en) * | 2020-03-13 | 2021-12-06 | 영진약품 주식회사 | Novel compounds of inhibiting cdk7, and their pharmaceutically acceptable salts |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| CA2332325A1 (en) | 1998-06-18 | 1999-12-23 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| GEP20105095B (en) * | 2001-07-19 | 2010-10-25 | Pfizer Italia Srl | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| MX2007001846A (en) * | 2004-08-17 | 2007-03-28 | Hoffmann La Roche | Substituted hydantoins. |
| US20090264415A2 (en) * | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
| EP1948629A1 (en) | 2005-10-31 | 2008-07-30 | Janssen Pharmaceutica N.V. | Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2008138755A2 (en) | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
| US20110263564A1 (en) * | 2008-10-29 | 2011-10-27 | Sirtris Pharmaceuticals, Inc. | Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
| WO2011079036A1 (en) * | 2009-12-22 | 2011-06-30 | The Translational Genomics Research Institute | Benzamide derivatives |
| US8952004B2 (en) * | 2010-01-07 | 2015-02-10 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| US8404859B2 (en) | 2011-03-16 | 2013-03-26 | Hoffmann-La Roche Inc. | Thiazole and thiophene compounds |
| WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6491202B2 (en) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7) |
| EP2878339A1 (en) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| PT3126352T (en) | 2014-04-04 | 2018-12-27 | Syros Pharmaceuticals Inc | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2016193939A1 (en) * | 2015-06-04 | 2016-12-08 | Aurigene Discovery Technologies Limited | Substituted heterocyclyl derivatives as cdk inhibitors |
-
2019
- 2019-09-11 CA CA3106855A patent/CA3106855A1/en not_active Abandoned
- 2019-09-11 MX MX2021002456A patent/MX2021002456A/en unknown
- 2019-09-11 WO PCT/KR2019/011887 patent/WO2020060112A1/en active Application Filing
- 2019-09-11 CN CN201980060101.9A patent/CN112739695A/en active Pending
- 2019-09-11 US US17/277,033 patent/US20210284658A1/en active Pending
- 2019-09-11 JP JP2021514364A patent/JP7235859B2/en active Active
- 2019-09-11 BR BR112021004999-1A patent/BR112021004999A2/en not_active Application Discontinuation
- 2019-09-11 EA EA202190558A patent/EA202190558A1/en unknown
- 2019-09-11 KR KR1020190113157A patent/KR102130253B1/en active IP Right Grant
- 2019-09-11 EP EP19862518.8A patent/EP3853225B1/en active Active
- 2019-09-11 UA UAA202101314A patent/UA125427C2/en unknown
- 2019-09-11 SG SG11202100531RA patent/SG11202100531RA/en unknown
- 2019-09-11 AU AU2019344240A patent/AU2019344240B2/en active Active
- 2019-09-11 IL IL280639A patent/IL280639B/en unknown
- 2019-09-17 TW TW108133355A patent/TW202023548A/en unknown
-
2020
- 2020-06-25 KR KR1020200078100A patent/KR20200078465A/en active Application Filing
-
2021
- 2021-03-10 CL CL2021000594A patent/CL2021000594A1/en unknown
- 2021-03-11 ZA ZA2021/01652A patent/ZA202101652B/en unknown
- 2021-03-15 PH PH12021550572A patent/PH12021550572A1/en unknown
- 2021-03-16 CO CONC2021/0003412A patent/CO2021003412A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020060112A1 (en) | 2020-03-26 |
| CO2021003412A2 (en) | 2021-04-08 |
| CN112739695A (en) | 2021-04-30 |
| ZA202101652B (en) | 2022-07-27 |
| BR112021004999A2 (en) | 2021-06-08 |
| PH12021550572A1 (en) | 2021-10-25 |
| EP3853225B1 (en) | 2023-11-29 |
| TW202023548A (en) | 2020-07-01 |
| EP3853225C0 (en) | 2023-11-29 |
| AU2019344240A1 (en) | 2021-02-25 |
| IL280639A (en) | 2021-03-25 |
| EP3853225A4 (en) | 2022-06-15 |
| EA202190558A1 (en) | 2022-02-03 |
| KR102130253B1 (en) | 2020-07-03 |
| US20210284658A1 (en) | 2021-09-16 |
| EP3853225A1 (en) | 2021-07-28 |
| JP2021535924A (en) | 2021-12-23 |
| MX2021002456A (en) | 2021-06-15 |
| KR20200078465A (en) | 2020-07-01 |
| CA3106855A1 (en) | 2020-03-26 |
| IL280639B (en) | 2022-07-01 |
| KR20200032002A (en) | 2020-03-25 |
| UA125427C2 (en) | 2022-03-02 |
| AU2019344240B2 (en) | 2022-09-29 |
| JP7235859B2 (en) | 2023-03-08 |
| CL2021000594A1 (en) | 2021-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL278171A (en) | Gip derivatives and uses thereof | |
| IL279101A (en) | Pharmaceutically acceptable salts of sepiapterin | |
| IL283533A (en) | Pantetheine derivatives and uses thereof | |
| IL283486A (en) | Microbiocidal thiazole derivatives | |
| EP3802495A4 (en) | Heterocyclic derivatives and use thereof | |
| SG11202010985TA (en) | Heterocyclic derivatives and use thereof | |
| IL279939A (en) | Thiadiazine derivatives | |
| SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
| ZA202106024B (en) | Heterocyclic derivatives | |
| IL282527A (en) | Azaindazole-5 derivatives and their use | |
| IL279441A (en) | N-substituted tetrahydrothienopyridine derivatives and uses thereof | |
| PT3796975T (en) | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| IL282526A (en) | Azaindazole-5 derivatives and their use | |
| ZA202101652B (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
| EP3773597A4 (en) | Phenothiazine derivatives and uses thereof | |
| IL282142A (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| LT3778609T (en) | Penam derivatives or salts thereof, pharmaceutical compositions and use thereof | |
| EP3409662A4 (en) | Novel compound and pharmaceutically acceptable salt thereof | |
| ZA202008062B (en) | Pharmaceutically acceptable salts of sepiapterin | |
| IL279928A (en) | Heterocyclic sulfonamide derivatives and pharmaceutical uses thereof | |
| EP3983415A4 (en) | Heterocyclic derivatives and use thereof | |
| FIC20190056I1 (en) | talazoparib, optionally in the form of a pharmaceutically acceptable salt | |
| HK1253072A1 (en) | Podophyllotoxin derivatives and their use |